Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 6/20 | 0.36 |
| ▸ | RXRA | P19793 | 2/20 | 0.34 |
| ▸ | RXRB | P28702 | 2/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | STK17B | O94768 | 1/20 | 0.32 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29439003 | 0.86 | SYK (0.37) | SYKLCKRXRARXRBRXRG | |
| SCHEMBL15747496 | 0.86 | SYK (0.37) | SYKLCKRXRARXRBRXRG | |
| SCHEMBL8819174 | 0.85 | SYK (0.37) | SYKLCKRXRARXRBRXRG | |
| SCHEMBL2788739 | 0.84 | SYK (0.34) | SYKLCKCYP2C9CYP2C19NPSR1 | |
| SCHEMBL8819965 | 0.82 | SYK (0.35) | SYKHSP90AA1HSP90AB1LMNAKMT2A | |
| SCHEMBL17985525 | 0.81 | LCK (0.33) | LCKRXRARXRBRXRGHSP90AA1 | |
| SCHEMBL8819479 | 0.79 | RXRA (0.38) | SYKRXRARXRBRXRGHSP90AA1 | |
| SCHEMBL4439402 | 0.78 | POLB (0.49) | SYKRXRARXRBRXRGHSP90AA1 | |
| SCHEMBL18167877 | 0.78 | STK17B (0.37) | SYKLCKHSP90AA1HSP90AB1LMNA | |
| SCHEMBL1053992 | 0.78 | HSP90AA1 (0.36) | SYKLCKHSP90AA1HSP90AB1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227333-B2 | Inhibition of OLIG2 activity | Curtana Pharmaceuticals, Inc. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20160237069-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2016-08-18 | — | — | US | disclosed |
| US-20160237069-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2016-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227333-B2 | Inhibition of OLIG2 activity | GLI2, ING2, GMFG | SYK 4535/4885LCK 2686/4885RXRA 1407/4885 |
| US-20160237069-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | SYK 4535/4885LCK 2686/4885RXRA 1407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.